ArticleHuman genomics2015
Success stories in genomic medicine from resource-limited countries.
Article in Human genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions.European journal of human genetics : EJHG · 2026Review
- A call to action for pharmacogenomics stewardship in South Africa.Frontiers in pharmacology · 2026Article
- Pharmacists' perspectives on integrating pharmacogenetics in clinical practice.Human genomics · 2025Article
- Implementing health economics for pharmacogenomics research translation in Africa.Communications medicine · 2025Review
- Bridging the gap: understanding the perspective of healthcare professional students towards precision medicine in a Nigerian tertiary institution (a cross-sectional study).BMC medical education · 2025Article
- Equity in action: The Diagnostic Working Group of The Undiagnosed Diseases Network International.NPJ genomic medicine · 2024Review
- Integrating Genetic Services in the Philippine Public Health Delivery System: The Value of Networks.Genes · 2024Article
- Historical evolution of cancer genomics research in Latin America: a comprehensive visual and bibliometric analysis until 2023.Frontiers in genetics · 2024Article
- Article
- Methods in molecular biology and genetics: looking to the future.BMC research notes · 2023Article
- Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Annual review of genomics and human genetics · 2022Review
- Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response.Journal of clinical medicine · 2022Article
- A View on Genomic Medicine Activities in Africa: Implications for Policy.Frontiers in genetics · 2022Article
- African genetic diversity and adaptation inform a precision medicine agenda.Nature reviews. Genetics · 2021Review
- Precision Medicine in Control of Visceral Leishmaniasis Caused byFrontiers in cellular and infection microbiology · 2021Review
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Knowledge and Attitudes of Medical and Health Science Students in the United Arab Emirates toward Genomic Medicine and Pharmacogenomics: A Cross-Sectional Study.Journal of personalized medicine · 2020Article
- Roadmap for Establishing Large-Scale Genomic Medicine Initiatives in Low- and Middle-Income Countries.American journal of human genetics · 2020Article
- Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.JCO global oncology · 2020Review
- Implementation and obstacles of pharmacogenetics in clinical practice: An international survey.British journal of clinical pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the translation of genomic discoveries into mainstream medical practice and public health has gained momentum, facilitated by the advent of new technologies. However, there are often major discrepancies in the pace of implementation of genomic medicine between developed and developing/resource-limited countries. The main reason does not only lie in the limitation of resources but also in the slow pace of adoption of the new findings and the poor understanding of the potential that this new discipline offers to rationalize medical diagnosis and treatment. Here, we present and critically discuss examples from the successful implementation of genomic medicine in resource-limited countries, focusing on pharmacogenomics, genome informatics, and public health genomics, emphasizing in the latter case genomic education, stakeholder analysis, and economics in pharmacogenomics. These examples can be considered as model cases and be readily replicated for the wide implementation of pharmacogenomics and genomic medicine in other resource-limited environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.